952510-14-4

952510-14-4 structure

Name: ASP-4058 hydrochloride
Chemical Name: ASP-4058 HYDROCHLORIDE
CAS Number: 952510-14-4
Molecular Formula: C₁₉H₁₃ClF₆N₄O₂
Molecular Weight: 478.78
Catalog: Signaling Pathways GPCR/G Protein LPL Receptor
Create Date: 2022-01-01 21:07:24
Modify Date: 2025-08-27 15:18:11
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile[1].

Name	ASP-4058 HYDROCHLORIDE
Synonyms	1H-Benzimidazole, 5-[5-[3-(trifluoromethyl)-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-, hydrochloride (1:1) 5-{5-[3-(Trifluoromethyl)-4-{[(2S)-1,1,1-trifluoro-2-propanyl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-benzimidazole hydrochloride (1:1) ASP-4058 HYDROCHLORIDE

Description	ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> LPL Receptor Research Areas >> Inflammation/Immunology
In Vivo	ASP4058 (p.o., daily for 21 days) hydrochloride reduces the clinical score in a dose-dependent manner and the cumulative clinical score from day 0 to 21 dpi at 0.03, 0.1 and 0.3 mg/kg are 15.5±1.48, 9.50±2.17 and 1.17±1.17, respectively, while that of vehicle-treated group is 15.5±0.619 in rats. ASP4058 prevents decreases in body weight of EAE rats[1]. ASP4058 (p.o., daily for day 12 to day 45) hydrochloride maintains the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi) among the groups treated with 0.1 and 0.3 mg/kg dosages are 6.90±2.85 and 5.60±2.21, respectively in mice. The ED50 values for ASP4058 is 0.063 mg/kg[1].
References	[1]. Rie Yamamoto, et al. ASP4058, a Novel Agonist for Sphingosine 1-Phosphate Receptors 1 and 5, Ameliorates Rodent Experimental Autoimmune Encephalomyelitis with a Favorable Safety Profile. PLoS One. 2014 Oct 27;9(10):e110819.